Literature DB >> 15536342

p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry.

Karen Curtin1, Martha L Slattery, Richard Holubkov, Sandra Edwards, Joseph A Holden, Wade S Samowitz.   

Abstract

This study compares single-strand conformation polymorphism (SSCP)/sequencing and immunohistochemistry (IHC) in a population-based colon cancer study to determine the best methods to evaluate p 53 alterations in tumors. Epidemiologic data collected from the Utah portion of a multicenter case-control study of colon cancer (n = 268) was used to compare somatic p53 mutations detected using SSCP/sequencing of exons 5 through 8 with those with p53 protein overexpression detected by IHC. A total of 136 tumors (51%) had p 53 mutations identified using SSCP/sequencing. IHC detected 164 tumors (61%) with protein overexpression (using a cut point of > or =20% positive cells) and 142 tumors (53%) when > or =50% positive cells were used. Sensitivity of IHC (> or =20% level) using SSCP/sequencing as the reference method was 85%. Specificity of IHC (> or =20% level) using SSCP/sequencing as reference was 63%. When > or =50% positive cells were used, specificity increased to 77%. Associations with age, gender, tumor site, stage, and Ki-ras were similar for both methods. An inverse relationship between microsatellite instability and p 53 was detected with the higher threshold for IHC positivity and SSCP/sequencing. SSCP/sequencing was able to discriminate between mutated p 53 and wild-type p 53 when evaluating dietary associations whereas IHC was not able to discriminate between these tumor types. Using a level of 50% or more positive cells increases specificity relative to sensitivity in comparison with lower staining levels, and is comparable with sequencing in its ability to detect an inverse relationship with the MSI. Advantages gained by sequencing are its ability to examine specific mutations and the improved ability to discriminate between cases with p 53 mutation and wild type when evaluating associations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536342     DOI: 10.1097/00129039-200412000-00017

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  15 in total

1.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Zhi Rong Qian; Reiko Nishihara; Kaori Sato; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

2.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Authors:  Shuji Ogino; Mohan Brahmandam; Takako Kawasaki; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study.

Authors:  Samir Gupta; Han Sun; Sang Yi; Joy Storm; Guanghua Xiao; Bijal A Balasubramanian; Song Zhang; Raheela Ashfaq; Don C Rockey
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-04

4.  A comparison of colon and rectal somatic DNA alterations.

Authors:  Martha L Slattery; Karen Curtin; Roger K Wolff; Kenneth M Boucher; Carol Sweeney; Sandra Edwards; Bette J Caan; Wade Samowitz
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

5.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.

Authors:  Shuji Ogino; Gregory J Kirkner; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Aditi Hazra; Andrew T Chan; Reiko Dehari; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression.

Authors:  Eva S Schernhammer; Shuji Ogino; Charles S Fuchs
Journal:  Gastroenterology       Date:  2008-06-12       Impact factor: 22.682

7.  Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women.

Authors:  Lori S Tillmans; Robert A Vierkant; Alice H Wang; N Jewel Samadder; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-16       Impact factor: 4.254

8.  Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Kaori Shima; Yoshifumi Baba; Gregory J Kirkner; Mari Mino-Kenudson; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Am J Gastroenterol       Date:  2009-10-06       Impact factor: 10.864

9.  Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis.

Authors:  P Qu; H Chu; J G Ibrahim; J Peacock; X J Shen; J Tepper; R S Sandler; T O Keku
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

10.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.